www.pediatriepropraxi.cz 341 FIREMNÍ INFORMACE Co přineslo postcovidové období v oblasti chřipkovitých onemocnění PEDIATRIE PRO PRAXI dvě modality imunostimulace v prevenci a terapii ILI: působení vitaminu C v komplexním posilování protiinfekční imunity a léčivý přípravek Prevac s obsahem fytoterapeutických a dalších složek, zaměřený na chřipkové stavy. Je zmíněna výhodnost přípravků řady Lipo C Askor s lipozomálním vstřebáváním, u kterých jsou součástí balení detekční proužky, umožňující orientační vyšetření saturace organismu vitaminem C. Oba uvedené způsoby prevence a léčby ILI se svými účinky doplňují. Článek uvádí i výsledky výzkumu deficitu vitaminu C u českých nemocných dětí a možnosti odstranění tohoto deficitu suplementací přípravku s lipozomálním vstřebáváním. LITERATURA 1. Spencer JA, Shutt DP, Moser SK, et al. Distinguishing viruses responsible for influenza-like illness. J Theor Biol. 2022; 545:111145. 2. Davis HE, Assaf GS, McCorkell L, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133-146. 3. Lage SL, Bricker-Holt K, Rocco JM, et al. Persistent immune dysregulation and metabolic alterations following SARS- -CoV-2 infection. medRxiv. 2025; 2025.04.16.25325949. 4. Peluso MJ, Deeks SG. Mechanisms of long COVID and the path toward therapeutics. Cell. 2024;187:5500-5529. 5. Gupta G, Buonsenso D, Wood J, et al. Mechanistic insights into Long COVID: viral persistence, immune dysregulation, and multi-organ dysfunction. Compr Physiol. 2025;15:e70019. 6. Notarte KI, Carandang THDC, Velasco JV, et al. Autoantibodies in COVID-19 survivors with post-COVID symptoms: a systematic review. Front Immunol. 2024;15:1428645. 7. Yin K, Peluso MJ, Luo X, et al. Long COVID manifests with T cell dysregulation and exhausted SARS-CoV-2-specific CD8+ T cells. Nat Immunol. 2024;25:218-225. 8. Cwilichowska-Puslecka N, Makowiecka A, Kalinka M, et al. Understanding the long-term interplay of SARS-CoV-2 and immune recovery. Front Immunol. 2025;16:1517933. 9. Mandel H, Yoo YJ, Allen AJ, et al. Long COVID incidence proportion in adults and children between 2020 and 2024: an electronic health record-based study from the RECOVER Initiative. Clin Infect Dis. 2025;80:1247-1261. 10. Ewing AG, Joffe D, Blitshteyn S, et al. Long COVID clinical evaluation, research and impact on society: a global expert consensus. Ann Clin Microbiol Antimicrob. 2025;24:27. 11. Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9:1211. 12. Vollbracht C, Raithel M, Krick B, et al. Intravenous vitamin C in the treatment of allergies: an interim subgroup analysis of a long-term observational study. J Int Med Res. 2018;46:3640-3655. 13. Uesato S, Kitagawa Y, Kaijima T, et al. Inhibitory effects of 6-O-acylated L-ascorbic acids possessing a straight- or branched-acyl chain on Epstein-Barr virus activation. Cancer Lett. 2001;66:143-146. 14. Cinatl J, Cinatl J, Weber B, et al. In vitro inhibition of human cytomegalovirus replication in human foreskin fibroblasts and endothelial cells by ascorbic acid 2-phosphate. Antiviral Res. 1995;27:405-418. 15. Leibovitz B, Siegel BV. Ascorbic acid and the immune response. Adv Exp Med Biol. 1981;135:1-25. 16. Kim Y, Kim H, Bae S, et al. Vitamin C is an essential factor on the anti-viral immune response through the production of interferon-alpha/beta at the initial stage of influenza A virus (H3N2) infection. Immune Netw. 2013;13:70-74. 17. Li W, Maeda N, Beck MA. Vitamin C deficiency increases the lung pathology of influenza virus-infected gulo-/- mice. J Nutr. 2006;136:2611-2616. 18. Cai Y, Li YF, Tang LP, et al. A new mechanism of vitamin C effects on A/FM/1/47(H1N1) virus-induced pneumonia in restraint-stressed mice. Biomed Res Int. 2015;2015:675149. 19. Kataoka A, Imai H, Inayoshi S, et al. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy. J Neurol Neurosurg Psy. 1993;56:1213-1216. 20. Harakeh S. NF-kappa B-independent suppression of HIV expression by ascorbic acid. AIDS Res Hum Retroviruses. 1997;13:235-239. 21. Hosakote YM, Jantzi PD, Esham DL, et al. Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2011;183:1550-1560. 22. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140:533-537. 23. Ahn H, Park JH. Liposomal delivery systems for intestinal lymphatic drug transport. Biomater Res. 2016;20:36. 24. Fan C, Pacier C, Martirosyan DM. Rose hip (Rosa canina L): A functional food perspective. Funct Foods Health Dis. 2014;4:493-509. 25. Boženský J, Kopřiva F, Kotlářová L, et al. Vitamin C, antiinfekční imunita a problematika snížených hladin u dětí. Pediatr praxi. 2021;22(2):98-104. 26. Mousa HAL. Prevention and treatment of influenza, influenza-like illness, and common cold by herbal, complementary, and natural therapies. J Evid Based Complementary Altern Med 2017;22:66-174. 27. Colombo M, Rigamonti G, Danza ML, et al. Comparative evaluation of Guna–Flu vs vaccine for the prevention of influenza syndrome in paediatrics – A prospective, multicentric randomized, controlled clinical trial. Physiological Regulating Medicine. 2007;2(1):3-10. 28. Supino C. Prevenzione delle infezioni delle alte vie respiratporie in eta pediatrica con Omeogriphi: studio multicentrico controllato. La Medicina Biologica. 2002;20(3): 19-23. 29. Arrighi A. Omeogriphi vs. paracetamolo nel trattamento della sindrome influenzale – studio clinico prosperrico controllato. La Medicina Biologica. 2013;31(4):3-12.
RkJQdWJsaXNoZXIy NDA4Mjc=